CU24631B1 - Método para inactivar xenoantígenos en tejidos biológicos - Google Patents
Método para inactivar xenoantígenos en tejidos biológicosInfo
- Publication number
- CU24631B1 CU24631B1 CU2018000048A CU20180048A CU24631B1 CU 24631 B1 CU24631 B1 CU 24631B1 CU 2018000048 A CU2018000048 A CU 2018000048A CU 20180048 A CU20180048 A CU 20180048A CU 24631 B1 CU24631 B1 CU 24631B1
- Authority
- CU
- Cuba
- Prior art keywords
- xenoantigens
- inactivate
- biological tissues
- tissues
- hydroxytyrosol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3625—Vascular tissue, e.g. heart valves
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
Abstract
<p>La presente invención se refiere a un método para inactivar xenoantígenos en tejidos biológicos aislados del cuerpo humano, que comprende: proporcionar una solución de ácido cafeico, de ácido tánico o de hidroxitirosol, para la inactivación del epítopo alfa-Gal de dichos tejidos; incubar las muestras y someter los tejidos tratados a tres lavados.</p>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITUB2015A006019A ITUB20156019A1 (it) | 2015-11-30 | 2015-11-30 | Metodo per l'inattivazione di xenoantigeni in tessuti biologici |
PCT/EP2016/078898 WO2017093147A1 (en) | 2015-11-30 | 2016-11-25 | Method for inactivating xenoantigens in biological tissues |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20180048A7 CU20180048A7 (es) | 2018-11-06 |
CU24631B1 true CU24631B1 (es) | 2022-12-12 |
Family
ID=55485194
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2018000048A CU24631B1 (es) | 2015-11-30 | 2016-11-25 | Método para inactivar xenoantígenos en tejidos biológicos |
Country Status (18)
Country | Link |
---|---|
US (1) | US20180353647A1 (es) |
EP (1) | EP3383446B1 (es) |
JP (1) | JP7169645B2 (es) |
KR (1) | KR20180090816A (es) |
CN (1) | CN108367098B (es) |
AU (1) | AU2016363536B2 (es) |
CA (1) | CA3006234A1 (es) |
CU (1) | CU24631B1 (es) |
DK (1) | DK3383446T3 (es) |
ES (1) | ES2881603T3 (es) |
IL (1) | IL259591B (es) |
IT (1) | ITUB20156019A1 (es) |
MX (1) | MX2018006577A (es) |
PL (1) | PL3383446T3 (es) |
RS (1) | RS62100B1 (es) |
RU (1) | RU2754197C2 (es) |
WO (1) | WO2017093147A1 (es) |
ZA (1) | ZA201803786B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201600115523A1 (it) * | 2016-11-16 | 2018-05-16 | Biocompatibility Innovation Srl | Metodo per l'inattivazione ed il controllo di avvenuta inattivazione di xenoantigeni in alimenti di origine animale, particolarmente per latte e derivati, e in alimenti di origine vegetale, particolarmente per succedanei di latte a base di soia e/o riso |
WO2020234845A1 (en) | 2019-05-22 | 2020-11-26 | Biocompatibility Innovation Srl | Method for preventing the formation of calcified deposits and for inactivating xenoantigens in biological matrices |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1396832A (zh) * | 2000-01-25 | 2003-02-12 | 内布拉斯加大学董事委员会 | 抵制抗供体免疫的移植前适应器官 |
US20040153145A1 (en) * | 2002-11-26 | 2004-08-05 | Clemson University | Fixation method for bioprostheses |
DK1734814T3 (en) * | 2004-03-17 | 2015-04-07 | Revivicor Inc | Tissue DERIVED FROM ANIMALS IS MISSING ANY EXPRESSION OF FUNCTIONAL ALPHA-1,3 galactosyltransferase |
BRPI0618485A2 (pt) * | 2005-11-10 | 2012-05-08 | Hills Pet Nutrition Inc | método, composição e kit para melhorar à saúde da pele e/ou a qualidade da pelagem de um animal, meio para comunicar informação ou instruções, e, uso de uma composição |
WO2007133479A2 (en) * | 2006-05-10 | 2007-11-22 | Cook Incorporated | Delivery of elastin-stabilizing compound within a body lumen |
CN101366979B (zh) * | 2008-09-03 | 2012-08-29 | 陕西瑞盛生物科技有限公司 | 一种组织补片及其制备方法 |
FR2947456B1 (fr) * | 2009-07-06 | 2012-03-09 | Univ Bordeaux 1 | Procede d'inactivation d'au moins un agent pathogene dans un echantillon de plasma sanguin humain |
IL210162A0 (en) * | 2010-12-21 | 2011-03-31 | Omrix Biopharmaceuticals | Viral inactivated platelet extract, use and preparation thereof |
JP2014516695A (ja) * | 2011-05-18 | 2014-07-17 | バトリックス・メディカル・インコーポレイテッド | 血管安定化用被覆バルーン |
RU2495928C2 (ru) * | 2012-01-30 | 2013-10-20 | Сергей Юрьевич Лешков | Средство для стимуляции синтеза белков теплового шока hsp 70 в клетках человека и животных; косметическое средство для стимуляции репаративных процессов; косметическое средство для снижения побочных эффектов агрессивных косметологических процедур; биологически активная добавка; пищевой продукт; способ снижения побочных эффектов агрессивных косметологических процедур |
ITPD20120029A1 (it) * | 2012-02-09 | 2013-08-10 | Alessandro Gandaglia | Metodo per la rilevazione di uno xenoantigene in tessuti fissati usati come sostituti bioprotesici |
US9795573B2 (en) * | 2013-09-24 | 2017-10-24 | Clemson University | Multi-step connective tissue stabilization method and stabilized tissue formed thereby |
-
2015
- 2015-11-30 IT ITUB2015A006019A patent/ITUB20156019A1/it unknown
-
2016
- 2016-11-25 RS RS20210866A patent/RS62100B1/sr unknown
- 2016-11-25 CU CU2018000048A patent/CU24631B1/es unknown
- 2016-11-25 US US15/779,953 patent/US20180353647A1/en active Pending
- 2016-11-25 RU RU2018123621A patent/RU2754197C2/ru active
- 2016-11-25 PL PL16801773T patent/PL3383446T3/pl unknown
- 2016-11-25 MX MX2018006577A patent/MX2018006577A/es unknown
- 2016-11-25 CA CA3006234A patent/CA3006234A1/en active Pending
- 2016-11-25 DK DK16801773.9T patent/DK3383446T3/da active
- 2016-11-25 CN CN201680069993.5A patent/CN108367098B/zh active Active
- 2016-11-25 EP EP16801773.9A patent/EP3383446B1/en active Active
- 2016-11-25 JP JP2018546756A patent/JP7169645B2/ja active Active
- 2016-11-25 ES ES16801773T patent/ES2881603T3/es active Active
- 2016-11-25 KR KR1020187016622A patent/KR20180090816A/ko active Search and Examination
- 2016-11-25 AU AU2016363536A patent/AU2016363536B2/en active Active
- 2016-11-25 WO PCT/EP2016/078898 patent/WO2017093147A1/en active Application Filing
-
2018
- 2018-05-24 IL IL259591A patent/IL259591B/en unknown
- 2018-06-07 ZA ZA2018/03786A patent/ZA201803786B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3383446A1 (en) | 2018-10-10 |
IL259591B (en) | 2022-04-01 |
EP3383446B1 (en) | 2021-04-28 |
AU2016363536A1 (en) | 2018-06-28 |
JP7169645B2 (ja) | 2022-11-11 |
DK3383446T3 (da) | 2021-07-26 |
ITUB20156019A1 (it) | 2017-05-30 |
KR20180090816A (ko) | 2018-08-13 |
RU2018123621A (ru) | 2020-01-09 |
JP2019503821A (ja) | 2019-02-14 |
CU20180048A7 (es) | 2018-11-06 |
IL259591A (en) | 2018-07-31 |
CA3006234A1 (en) | 2017-06-08 |
PL3383446T3 (pl) | 2021-11-02 |
MX2018006577A (es) | 2018-09-05 |
US20180353647A1 (en) | 2018-12-13 |
BR112018011021A2 (pt) | 2018-11-21 |
RS62100B1 (sr) | 2021-08-31 |
RU2754197C2 (ru) | 2021-08-30 |
CN108367098B (zh) | 2021-06-11 |
ZA201803786B (en) | 2019-02-27 |
ES2881603T3 (es) | 2021-11-30 |
AU2016363536B2 (en) | 2021-04-01 |
RU2018123621A3 (es) | 2020-04-10 |
WO2017093147A1 (en) | 2017-06-08 |
CN108367098A (zh) | 2018-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2017004715A2 (es) | Métodos y formulaciones para tratar enfermedades vasculares de los ojos | |
DOP2017000186A (es) | Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes | |
CL2017002728A1 (es) | Método para el tratamiento de cáncer | |
GT201700081A (es) | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas | |
UY36458A (es) | Anticuerpos humanos para hemaglutinina influenza. | |
CO6640274A2 (es) | Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes | |
UY33047A (es) | Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes | |
BR112017022768A2 (pt) | desinfecção de tecido com ondas de choque de pressão acústica | |
CO2017000571A2 (es) | Procedimiento de inactivación de inmunoglobulina endógena que permite facilitar procedimientos médicos que se ven afectados por la presencia de inmunoglobulina endógena | |
CO6950476A2 (es) | Derivados de 8-carbamoil-2-(2,3- pirid- 6- ilo di sustituido) -1,2,3,4 -tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes | |
CR20160269A (es) | Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento del cancer y enfermedades comunes | |
BR112015021115A2 (pt) | agentes para induzir apoptose para o tratamento de câncer e doenças imunes e autoimunes | |
AR091316A1 (es) | Moleculas de union humanas que se pueden unir y neutralizar a los virus de la influenza b y sus usos | |
CL2019000304A1 (es) | Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento. | |
ECSP12012017A (es) | DERIVADOS DE SULFONAMIDA COMO AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 PARA EL TRATAMIENTO DE CÁNCER Y ENFERMEDADES INMUNES | |
CL2014000432A1 (es) | Compuestos derivados de clorofila o bacterioclorofila; composicion farmaceutica que los comprende; y metodo de tratamiento fotodinamico del adelgazamiento de la cornea o del estiramiento de la esclerotica. | |
GT201600084A (es) | (aza) piridopirazolopirimidinonas e indazolopirimidinonas y su uso | |
CY1122615T1 (el) | Θεραπεια με βλαστοκυτταρα σε παθολογιες τουενδομητριου | |
BR112016026545A8 (pt) | eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama | |
AR104598A1 (es) | Métodos para tratar trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con células t | |
CL2017003309A1 (es) | Métodos de purificación y/o inactivación viral | |
CY1124492T1 (el) | 7-υποκατεστημενα 1-αρυλο-ναφθυριδιν-3-καρβοξαμιδια και η χρηση αυτων | |
BR112016028895A2 (pt) | composições biofotônicas termofixas e usos destas | |
BR112018009004A8 (pt) | conjugados anti-cd3-folato e seus usos | |
CU24631B1 (es) | Método para inactivar xenoantígenos en tejidos biológicos |